Next & Bio

Next&Bio is a South Korean biotechnology company specializing in organoid technology for precision medicine and drug discovery. The company develops standardized, high-throughput organoid culture platforms that replicate human organ structures and functions to improve the accuracy of drug efficacy and toxicity testing. Their core business includes organoid-based diagnostic services for personalized cancer treatment and collaborative R&D with pharmaceutical companies for drug screening. In 2022, Next&Bio was acquired by Kolmar Korea Holdings, integrating its advanced organoid capabilities into a broader healthcare and cosmetics ecosystem. The company is actively establishing a global standard for organoid-based clinical trials and is expanding its pipeline into cell therapies and regenerative medicine.